Comprehensive Lancet Review Reaffirms Safety, Effectiveness of mRNA Vaccines

A new review published in The Lancet has reaffirmed that currently approved messenger RNA (mRNA) vaccines remain safe and highly effective, drawing on data from billions of administered doses across diverse populations, including children, pregnant individuals, and immunocompromised patients. The analysis—which was led by investigators from the University of British Columbia and Imperial College London—pooled laboratory research, clinical trial results, and real-world surveillance data to evaluate the safety profile and the public health impact of mRNA vaccination since its emergency rollout during the COVID-19 pandemic.^1,2

Effectiveness Holds Up, Even as Variants Emerge

According to the review, mRNA vaccines were approximately 87% effective against any documented SARS-CoV-2 infection, 93% effective against hospitalization, and 94% effective against mortality within 14 to 42 days of vaccination. Effectiveness waned over time and was somewhat reduced against the Omicron lineage, but booster doses meaningfully restored protection. For pharmacists fielding patient questions about waning immunity, these findings reinforce existing booster guidance and underscore the importance of staying current on seasonal updates.^1,2

Putting Adverse Event Rates in Context

Serious adverse events (AEs) following mRNA vaccination remain rare, the review found. Myocarditis and pericarditis, the most closely monitored safety signals, occurred at roughly 12.6 cases per million second doses for BNT162b2 and 35.6 cases per million for mRNA-1273, with elevated risk concentrated in males aged 12 to 19. These figures are broadly consistent with CDC's ongoing Vaccine Adverse Event Reporting System (VAERS) surveillance, which has tracked myocarditis cases since the vaccines' authorization and found that most reported cases are mild and resolve quickly. Independent literature reviews have similarly characterized vaccine-associated myocarditis as rare but clinically notable, advising clinicians to maintain a high index of suspicion in young male patients presenting with chest pain within a week of vaccination. Anaphylaxis (4.7 cases per million Pfizer doses) and Guillain-Barré syndrome (38 cases per million AstraZeneca doses) were also rare, with mild reactions including sore arms, fatigue, and fever accounting for the bulk of reported AEs.^1-4

A Platform With Broader Potential

Beyond COVID-19, the review's authors highlighted the mRNA platform's versatility, noting active development of vaccines targeting influenza, respiratory syncytial virus, and other infectious diseases, as well as personalized cancer vaccines and RNA-based therapeutics. This mirrors the rapid trajectory the platform has already taken: the first mRNA vaccines received FDA approval for emergency use in late 2020, building on decades of foundational research before scaling to hundreds of millions of administered doses within roughly 2 years.^1,2,5

Addressing Access and Pharmacist Communication Needs

The study authors called for expanded manufacturing capacity in low- and middle-income countries and improved cold-chain and storage technology to widen global access. They also emphasized continued, clear communication about vaccine safety to counter misinformation, a role pharmacists are well positioned to fill given their frequent, trusted interactions with patients at the point of care.¹

What This Means for Pharmacy Practice

For pharmacists administering vaccines or counseling patients, this review offers a useful, consolidated reference point. The consistency of safety and effectiveness data across billions of doses, paired with transparent reporting of rare AEs, supports continued confidence in mRNA vaccination programs while reinforcing the value of ongoing postmarketing surveillance. As mRNA technology expands into new disease areas, pharmacists may increasingly find themselves explaining not just COVID-19 vaccination but a growing platform of RNA-based prevention and treatment options to patients.^1-4

REFERENCES

1. Blakney A, Top K, Cowling B et al. Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective. The Lancet. 2026. doi:10.1016/S0140-6736(26)00512-X

2. The Lancet: Currently approved mRNA vaccines are safe and effective, with promise for future disease prevention and treatment, new review confirms. News release. EurekAlert! June 30, 2026. Accessed July 1, 2026. https://www.eurekalert.org/news-releases/1133988

3. Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/

4. COVID-19 vaccine-associated myocarditis. PMC (National Institutes of Health). 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9350606/

5. Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine [ClinicalTrials.gov protocol referencing FDA approval history of mRNA-1273 and BNT162b2]. https://cdn.clinicaltrials.gov/large-docs/86/NCT05477186/Prot_000.pdf